RT Journal Article
SR Electronic
T1 Single-cell atlas of transcriptomic vulnerability across multiple neurodegenerative and neuropsychiatric diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.31.24316513
DO 10.1101/2024.10.31.24316513
A1 Lee, Donghoon
A1 Koutrouli, Mikaela
A1 Masse, Nicolas Y.
A1 Hoffman, Gabriel E.
A1 Kinrot, Seon
A1 Wang, Xinyi
A1 Prashant, N.M.
A1 Pjanic, Milos
A1 Clarence, Tereza
A1 Tsetsos, Fotios
A1 Mathur, Deepika
A1 Burstein, David
A1 Therrien, Karen
A1 Hong, Aram
A1 Casey, Clara
A1 Shao, Zhiping
A1 Alvia, Marcela
A1 Argyriou, Stathis
A1 Monteiro Fortes, Jennifer
A1 Katsel, Pavel
A1 Auluck, Pavan K.
A1 Barnes, Lisa L.
A1 Marenco, Stefano
A1 Bennett, David A.
A1 PsychAD Consortium
A1 Jensen, Lars Juhl
A1 Girdhar, Kiran
A1 Voloudakis, Georgios
A1 Haroutunian, Vahram
A1 Bendl, Jaroslav
A1 Fullard, John F.
A1 Roussos, Panos
YR 2024
UL http://medrxiv.org/content/early/2024/11/04/2024.10.31.24316513.abstract
AB Neurodegenerative and neuropsychiatric diseases impose a significant societal and public health burden. However, our understanding of the molecular mechanisms underlying these highly complex conditions remains limited. To gain deeper insights into the etiology of different brain diseases, we used specimens from 1,494 unique donors to generate a population-scale single-cell transcriptomic atlas of the human dorsolateral prefrontal cortex (DLPFC), comprising over 6.3 million individual nuclei. The cohort includes neurotypical controls as well as donors affected by eight common and complex brain disorders: Alzheimer’s disease (AD), diffuse Lewy body disease (DLBD), vascular dementia (Vas), Parkinson’s disease (PD), tauopathy, frontotemporal dementia, schizophrenia, and bipolar disorder. We show that inter-individual variation accounts for a substantial portion of gene expression variation in the DLPFC. By comparing transcriptomic variation across diseases, we reveal universal signatures enriched in basic cellular functions such as mRNA splicing and protein localization. After discounting these cross-disease signatures, we show strong genetic and transcriptomic concordance among AD, DLBD, Vas, and PD, largely driven by alteration of synaptic signaling functions in neurons. Furthermore, we characterize transcriptomic variation among different AD phenotypes that were distinct from healthy aging. We uncover mitigating effects of interneurons and aggravating effects of immune and vascular cells in AD dementia. Further exploring the effect of the neuropsychiatric symptoms frequently accompanying AD, we identify a link to deep layer excitatory neurons. By constructing transcriptome trajectories that capture AD progression, we show cell-type specific responses implicated in early and late stages of AD. Our atlas provides an unprecedented perspective of the transcriptomic landscape in neurodegenerative and neuropsychiatric diseases, shedding light on shared and distinct processes involving the neuro-immune-vascular systems, and identifying potential targets for therapeutic intervention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge the National Institute on Aging for their generous support in funding this research with the following NIH grants: R01AG067025, R01AG082185, and R01AG065582. Human tissues were obtained from the NIH NeuroBioBank at the Mount Sinai Brain Bank (MSSM; supported by NIMH-75N95019C00049), the Rush Alzheimer's Disease Center (RADC; funding: P30AG10161, P30AG72975, R01AG15819, R01AG17917, R01AG22018, U01AG46152, and U01AG61356), and NIMH-IRP Human Brain Collection Core (HBCC, project # ZIC MH002903). This work was also supported by the Novo Nordisk Foundation NNF14CC0001 and NNF20SA0035590.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Mount Sinai gave ethical approval for this work. Ethics committee/IRB of James J. Peters Department of Veterans Affairs Medical Center gave ethical approval for this work. Ethics committee/IRB of Rush Alzheimer's Disease Center gave ethical approval for this work. Ethics committee/IRB of National Institute of Mental Health Human Brain Collection Core gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data are available via the AD Knowledge Portal (https://adknowledgeportal.org). The AD Knowledge Portal is a platform for accessing data, analyses, and tools generated by the Accelerating Medicines Partnership (AMP-AD) Target Discovery Program and other National Institute on Aging (NIA)-supported programs to enable open-science practices and accelerate translational learning. The data, analyses and tools are shared early in the research cycle without a publication embargo on secondary use. Data is available for general research use according to the following requirements for data access and data attribution (https://adknowledgeportal.synapse.org/Data%20Access). The data are available under controlled use conditions set by human privacy regulations. To access the data, a data use agreement is needed. The registration is in place solely to ensure the anonymity of the study participants. In addition, we have a data descriptor manuscript102 detailing the data processing and data collection.